Search results
Showing 826 to 840 of 2182 results for guidelines
The PressureWire fractional flow reserve measurement system for coronary artery disease (MIB2)
NICE has developed a Medtech Innovation Briefing (MIB) on the PressureWire fractional flow reserve measurement system
Evidence-based recommendations on liraglutide (Saxenda) for managing overweight and obesity alongside a reduced-calorie diet and increased physical activity in adults.
NICE no longer plans to develop guidance on Freelite assays for diagnosing multiple myeloma and related conditions in primary care.
Show all sections
Sections for HTG619
Axonics sacral neuromodulation system for faecal incontinence (MIB259)
NICE has developed a medtech innovation briefing (MIB) on Axonics sacral neuromodulation system for faecal incontinence .
Asthma. Patient decision aid on asthma inhalers and climate change (BTS, NICE, SIGN)
decision aid reflects the commitment of NICE, the Scottish Intercollegiate Guidelines Network (SIGN) and the British Thoracic Society...
Evidence-based recommendations on endoscopic sleeve gastroplasty for obesity. This involves using an endoscopic device to fold the stomach in on itself and stitch it together to reduce its volume.
View recommendations for HTG711Show all sections
Evidence-based recommendations on sacubitril valsartan (Entresto) for treating symptomatic chronic heart failure with reduced ejection fraction.
In development Reference number: GID-TA11960 Expected publication date: 24 February 2027
This indicator covers the percentage of mothers who give their babies breast milk in the first 48 hours after delivery. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG33
EarlyCDT Lung for assessing risk of lung cancer in solid lung nodules (HTG611)
Evidence-based recommendations on EarlyCDT Lung for assessing the risk of lung cancer in solid lung nodules.
Getting involved as a voluntary and community sector organisation
Getting involved with NICE as a voluntary and community sector organisation
Getting involved as a voluntary and community sector organisation
Getting involved with NICE as a voluntary and community sector organisation
Evidence-based recommendations on everolimus (Afinitor) and sunitinib (Sutent) for treating neuroendocrine tumours in adults.
This indicator covers the the percentage of patients with a current diagnosis of heart failure with reduced ejection fraction, who are currently treated with an angiotensin-converting enzyme inhibitor or angiotensin receptor-neprilysin inhibitor or angiotensin II receptor blocker, a beta blocker, a mineralocorticoid receptor antagonist and a sodium glucose co-transporter-2 inhibitor. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Evidence-based recommendations on 2 adjunctive colposcopy technologies (the DYSIS colposcope with DYSISmap and the ZedScan I) for assessing suspected cervical abnormalities in people having colposcopy.